Brian Adams

CIK: 0001636994

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)13 (76.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (23.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

KYMR

Kymera Therapeutics, Inc.

Officer

RLAY

Relay Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (17 total)

KYMR
Kymera Therapeutics, Inc.
Sep 4, 2026
Sale(S)
Direct
3K shares at avg. $116.81$353K
KYMR
Kymera Therapeutics, Inc.
Sep 4, 2026
Sale(S)
Direct
2.1K shares at avg. $117.57$251K
KYMR
Kymera Therapeutics, Inc.
Sep 4, 2026
Sale(S)
Direct
1.2K shares at avg. $115.55$140K
KYMR
Kymera Therapeutics, Inc.
Mar 2, 2026
Award(A)
Direct
4.1K shares-
KYMR
Kymera Therapeutics, Inc.
Sep 3, 2025
Award(A)
Direct
52.5K shares-
RLAY
Relay Therapeutics, Inc.
Jul 29, 2025
Sale(S)
Direct
18.3K shares at avg. $3.68$67K
RLAY
Relay Therapeutics, Inc.
Jul 28, 2025
Sale(S)
Direct
1.6K shares at avg. $3.74$6K
RLAY
Relay Therapeutics, Inc.
Apr 30, 2025
Sale(S)
Direct
12.9K shares at avg. $3.00$39K
RLAY
Relay Therapeutics, Inc.
Apr 28, 2025
Sale(S)
Direct
1.6K shares at avg. $3.17$5K
RLAY
Relay Therapeutics, Inc.
Mar 27, 2025
Sale(S)
Direct
298 shares at avg. $2.84$846.32
RLAY
Relay Therapeutics, Inc.
Jan 30, 2025
Sale(S)
Direct
20.8K shares at avg. $4.42$92K
RLAY
Relay Therapeutics, Inc.
Jan 28, 2025
Sale(S)
Direct
33.7K shares at avg. $4.63$156K
RLAY
Relay Therapeutics, Inc.
Jan 28, 2025
Award(A)
Direct
139.1K shares-
RLAY
Relay Therapeutics, Inc.
Jan 10, 2025
Award(A)
Stock Option (Right to Buy)
Direct
275K shares-
RLAY
Relay Therapeutics, Inc.
Dec 27, 2024
Sale(S)
Direct
299 shares at avg. $4.38$1K
RLAY
Relay Therapeutics, Inc.
Oct 28, 2024
Sale(S)
Direct
1.6K shares at avg. $6.06$10K
RLAY
Relay Therapeutics, Inc.
Sep 27, 2024
Sale(S)
Direct
295 shares at avg. $7.51$2K

		Type	Shares	Price		Ownership
Sep 4, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	3,025	$116.81	$353,350	Direct
Sep 4, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	2,137	$117.57	$251,247	Direct
Sep 4, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	1,209	$115.55	$139,700	Direct
Mar 2, 2026	KYMR Kymera Therapeutics, Inc.	Award(A)	4,125	-	$0	Direct
Sep 3, 2025	KYMR Kymera Therapeutics, Inc.	Award(A)	52,500	-	-	Direct
Jul 29, 2025	RLAY Relay Therapeutics, Inc.	Sale(S)	18,276	$3.68	$67,256	Direct
Jul 28, 2025	RLAY Relay Therapeutics, Inc.	Sale(S)	1,637	$3.74	$6,122	Direct
Apr 30, 2025	RLAY Relay Therapeutics, Inc.	Sale(S)	12,943	$3.00	$38,829	Direct
Apr 28, 2025	RLAY Relay Therapeutics, Inc.	Sale(S)	1,644	$3.17	$5,211	Direct
Mar 27, 2025	RLAY Relay Therapeutics, Inc.	Sale(S)	298	$2.84	$846	Direct
Jan 30, 2025	RLAY Relay Therapeutics, Inc.	Sale(S)	20,791	$4.42	$91,896	Direct
Jan 28, 2025	RLAY Relay Therapeutics, Inc.	Sale(S)	33,688	$4.63	$155,975	Direct
Jan 28, 2025	RLAY Relay Therapeutics, Inc.	Award(A)	139,141	-	$0	Direct
Jan 10, 2025	RLAY Relay Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	275,000	-	-	Direct
Dec 27, 2024	RLAY Relay Therapeutics, Inc.	Sale(S)	299	$4.38	$1,310	Direct
Oct 28, 2024	RLAY Relay Therapeutics, Inc.	Sale(S)	1,632	$6.06	$9,890	Direct
Sep 27, 2024	RLAY Relay Therapeutics, Inc.	Sale(S)	295	$7.51	$2,215	Direct

1-17 of 17 transactions

About Adams Brian

Adams Brian (SEC CIK 0001636994) files insider reports with the SEC as Chief Legal Officer of Kymera Therapeutics, Inc. (KYMR) and Chief Legal Officer of Relay Therapeutics, Inc. (RLAY).

Signal8 holds 12 ownership filings by Adams Brian (1 Form 3, 11 Form 4), filed between Oct 1, 2024 and Sep 4, 2026. Those filings report 17 transactions, from Sep 27, 2024 to Sep 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Adams Brian's filings is in WATERTOWN, MA.

Recent filings by Adams Brian

Sep 4, 2026: Open-market sales of KYMR shares (3 lines, Form 4, code S).
Mar 2, 2026: Grant or award of KYMR shares (Form 4, code A).
Sep 3, 2025: Grant or award of KYMR shares (Form 4, code A).
Jul 29, 2025: Open-market sale of RLAY shares (Form 4, code S).
Jul 28, 2025: Open-market sale of RLAY shares (Form 4, code S).

Other insiders filing for Kymera Therapeutics, Inc. (KYMR)

Mainolfi Nello, Chief Executive Officer
Rooney Terence, Chief Medical Officer
Jacobs Bruce N., Chief Financial Officer
Goodman Noah, Chief Business Officer
Booth Bruce, Director
BVF PARTNERS L P/IL, Director

How to read Form 4 transaction codes